iSpecimen 2025 Q3 Earnings Net Loss Widens by 93% Despite EPS Improvement

The earnings report reveals a stark contrast between narrowed per-share losses and a significantly wider net loss, underscoring operational challenges. The 96% revenue decline and persistent six-year quarterly losses highlight structural issues, while recent stock price declines reflect investor skepticism about the company’s path to sustainability.

Revenue

iSpecimen’s total revenue plummeted 96% year-over-year to $106,592 in Q3 2025, with its core specimens segment—driven by customer contracts—accounting for $95,816 of the total. Ancillary revenue streams, including shipping and other services, contributed an additional $10,776. The sharp contraction signals severe demand erosion and operational scaling challenges across its business lines.

Earnings/Net Income

While the company reduced its per-share loss to $0.48 from $2.10 (a 77.1% improvement), the net loss expanded to $2.78 million, a 93.1% increase from $1.44 million in the prior-year period. This divergence reflects aggressive cost-cutting measures offsetting broader financial deterioration. Despite improved efficiency, the company’s net loss trajectory remains deeply concerning, indicating insufficient revenue recovery to justify ongoing operations.

Price Action

iSpecimen’s stock has continued its downward spiral, with a 7.89% intraday drop, a 9.91% weekly decline, and a 28.19% monthly slump. The 30-day buy-and-hold strategy has yielded an average -6.59% return over the past year, despite a 71% success rate in trades, while the 3-month average of +11.61% offers limited optimism.

Additional News

Recent filings reveal a 76% year-over-year revenue decline to $1.88 million for the nine months ended September 30, 2025, accompanied by a $5.49 million net loss. Cost reductions and equity financings have stabilized short-term liquidity, but the SEC 10-Q report explicitly flags substantial doubt about the company’s ability to continue as a going concern. Management has not disclosed major strategic shifts or capital-raising plans beyond these measures, leaving long-term viability in question.